Composition for treating hashimoto thyroiditis as well as preparation method and application thereof
Through the effects of clearing heat, detoxifying, invigorating qi and promoting blood circulation of the composition of Kaoxixian and Artemisia tetraleum, the thyroid damage and inflammation problems in Hashimoto's thyroiditis treatment were solved, significantly improved the thyroid inflammation level, and provided an accurate and safe treatment plan.
Patent Information
- Application Number
- CN202411027052.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-30
- Publication Date
- 2024-12-03
AI Technical Summary
The existing technology lacks effective methods for treating Hashimoto's thyroiditis, especially ineffective in improving damage caused by the thyroid autoimmune response or delaying the progress of the disease. In addition, traditional Chinese medicine treatment has a long treatment cycle, inconsistent syndrome types, diverse treatment methods and lack of circulation. Problems of evidence of medical evidence.
The composition consisting of two medicinal herbs, Kaoxixian and Artemisia tetragonum multiflorum, has the effects of clearing heat and detoxifying, invigorating qi and promoting blood circulation. It is extracted and concentrated into an oral preparation for the treatment of Hashimoto's thyroiditis and reducing thyroid tissue enlargement. Reduce specific antibody titers and improve thyroid inflammation levels.
It significantly reduced the enlargement and inflammation of the thyroid tissue in mice, reduced the incidence and score of Hashimoto's thyroiditis, and reduced the lymphatic infiltration and follicular structure damage of the thyroid tissue, demonstrating the therapeutic effect of this composition.
Smart Images

Figure CN119055702A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of pharmaceutical technology, and in particular relates to a composition for treating Hashimoto's thyroiditis, a preparation method and application thereof. Background Art
[0002] Hashimoto's thyroiditis (HT) is an organ-specific immune disease characterized by autoantibodies and is one of the most common thyroid autoimmune diseases. The pathological characteristics of HT are chronic inflammation, accompanied by increased concentrations of thyroid peroxidase antibodies (TPO) and thyroglobulin antibodies (TgAb) in the circulation. Lymphocytes infiltrate the thyroid parenchyma, causing glandular enlargement, fibrosis, and follicular destruction, and progressive thyroid cell failure, resulting in hypothyroidism. In iodine-sufficient areas, HT is the main cause of hypothyroidism. The incidence of HT is increasing year by year, seriously affecting the health of patients. Therefore, it is of great significance to conduct in-depth research on the pathogenesis and intervention measures of HT.
[0003] For the treatment of HT, there is no definite treatment method in the existing technology that can effectively improve the damage caused by thyroid autoimmune response or delay the progression of HT. The main treatment for HT is to use thyroid hormone substitutes, such as levothyroxine sodium, to replenish hormone levels and maintain normal thyroid function. However, long-term and high-dose use of levothyroxine sodium can cause certain adverse reactions to organs such as the heart. Therefore, it is crucial to explore new therapies to improve immune imbalance, inhibit the occurrence of inflammation, and promote apoptosis of thyroid tissue cells.
[0004] There is no exact name for HT in traditional Chinese medicine. Most scholars classify it as "goiter" or "goiter" based on its clinical manifestations. Traditional Chinese medicine books point out that blood stasis, qi stagnation, and phlegm coagulation are the basic pathogenesis of goiter. The occurrence of goiter is closely related to geographical environment, improper diet, emotional disorders, etc. In terms of treatment, traditional Chinese medicine starts from multiple aspects, including liver treatment, qi, blood, phlegm and stasis treatment, treatment by type, treatment by stage, as well as internal and external treatment, combined Chinese and Western treatment, etc., and has achieved certain clinical efficacy. However, the views of various Chinese medicine schools are inconsistent, the syndrome types are not unified, the treatment methods are diverse, and there are shortcomings such as long treatment cycle and lack of evidence-based medicine. At present, the traditional Chinese medicine treatment of HT is still in the exploratory stage.
[0005] The present invention aims to provide a Wa ethnic minority compound prescription for treating Hashimoto's thyroiditis, which has definite efficacy and good safety. Summary of the invention
[0006] One of the purposes of the present invention is to provide a composition for treating Hashimoto's thyroiditis, which is composed of two herbs, Coxixin and Artemisia tetragonum, and has the effects of clearing away heat and detoxifying, invigorating qi and activating blood circulation. It is effective in treating Hashimoto's thyroiditis and has good safety.
[0007] The second object of the present invention is to provide a method for preparing the composition.
[0008] The third object of the present invention is to provide an application of the composition.
[0009] To achieve the above purpose, the technical solution adopted by the present invention is as follows:
[0010] The invention discloses a composition for treating Hashimoto's thyroiditis, which is prepared from the following raw materials in parts by weight: 80 to 120 parts of Coxisant and 80 to 120 parts of Artemisia tetragonum.
[0011] In some embodiments of the present invention, the drug is prepared from the following raw materials in parts by weight: 90-110 parts of Coxid and 90-110 parts of Artemisia tetragonum.
[0012] In some embodiments of the present invention, the drug is prepared from the following raw materials in parts by weight: 100 parts of Corsican and 100 parts of Artemisia tetragonum.
[0013] In some embodiments of the present invention, the composition is an oral preparation made from Coxisin and Artemisia tetragonum as raw materials.
[0014] In some embodiments of the present invention, the oral preparation includes an oral solid preparation, an oral liquid preparation, or an oral semisolid preparation.
[0015] The preparation method of the composition for treating Hashimoto's thyroiditis disclosed in the present invention comprises the following steps:
[0016] Weigh cosihan and Artemisia tetragonum according to proportion, add water to extract, concentrate and prepare an oral solution.
[0017] The method for preparing the composition for treating Hashimoto's thyroiditis disclosed in the present invention is characterized by comprising the following steps:
[0018] Weigh Coxixin and Artemisia tetragonum according to proportion, add water to extract, concentrate into a thick paste, add auxiliary materials, granulate, dry, and prepare granules.
[0019] In some embodiments of the present invention, the number of times of boiling with water is 1 to 5 times, preferably 1 to 3 times;
[0020] Add 5 to 8 times more water each time;
[0021] Preferably, before the first decoction, soak in water for 0.5 to 2 hours.
[0022] The invention discloses an application of the composition in preparing medicine for preventing and / or treating thyroiditis.
[0023] In some embodiments of the present invention, the composition is used in the preparation of a drug for preventing or / treating Hashimoto's thyroiditis.
[0024] The composition of the present invention is taken orally. When converted into crude drugs, 15-30 g of Coxid and 15-30 g of Artemisia tetragonum are taken orally per day, divided into 2-3 times per day.
[0025] The causinium described in the present invention is also known as yellow flower water lotus, which is the dried root of Polygalafallax Hemsl., a plant of the Polygalaceae family. The causinium is warm in nature and sweet in taste; it has the effects of invigorating qi and activating blood circulation, dispelling wind and removing dampness.
[0026] Artemisia eriocalyx, also known as hairy calyx tea, is the dried whole herb of Rabdosiaeriocalyx (Dunn) Haravar.eriocalyx of the Lamiaceae family. Artemisia eriocalyx is slightly cold in nature, bitter and sweet in taste, and enters the heart and liver meridians; it has the effects of dispelling wind and dampness, promoting blood circulation and relaxing muscles, clearing away heat and detoxifying, cooling blood and relieving pain.
[0027] The combination of Kaoxixian and Artemisia annua has the effects of clearing away heat, detoxifying, invigorating Qi and activating blood circulation.
[0028] Compared with the prior art, the present invention has the following beneficial effects:
[0029] The invention is scientifically designed, ingeniously conceived, and exquisitely formulated, with only two herbs in the whole prescription. Pharmacodynamic tests show that the composition of the invention can reduce the absolute and relative weight of the thyroid gland of mice, reduce the enlarged thyroid tissue of mice, reduce the incidence of Hashimoto's thyroiditis in mice, reduce the Hashimoto's thyroiditis score of mice, reduce the lymphatic infiltration and follicular structure destruction of the thyroid tissue of mice, and reduce the specific antibody titer level (TgAb) of mice in the model group. The composition of the invention can significantly improve NOD.H-2 h4 The thyroid inflammation level and overall immune activation level of mice are effective in treating Hashimoto's thyroiditis. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 Each group of NOD.H-2 of Test Example 1 of the present invention h4 Thyroid wet weight and relative weight of mice ([M(P25, P75)], n=35);
[0031] Figure 2 Each group of NOD.H-2 of Test Example 1 of the present invention h4 Results of investigation on the level of thyroid autoantibodies in mouse serum (TgAb) ( n=33);
[0032] Figure 3 Each group of NOD.H-2 of Test Example 1 of the present invention h4 HE staining of mouse thyroid gland (×400). DETAILED DESCRIPTION
[0033] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0034] The Coxixian and Artemisia annua slices used in the embodiments of the present invention were purchased from Yunnan Lvsheng Chinese Medicine Technology Co., Ltd.
[0035] Example 1
[0036] This embodiment discloses a method for preparing the composition of the present invention, which is as follows:
[0037] Take 100g of Coxixian and 100g of Artemisia tetragonum, add water and boil three times; add 8 times the amount of water for the first time, soak for 30 minutes and then boil for 2 hours, add 6 times the amount of water for the second and third times and boil for 1.5 hours. Filter, combine the filtrate, concentrate to a concentration of 2g / ml (based on the original medicinal materials), sterilize, and prepare an oral solution.
[0038] The dosage is 20 ml per day, divided into two or three doses.
[0039] Example 2
[0040] This embodiment discloses a method for preparing the composition of the present invention, which is as follows:
[0041] Take 80g of Coxixian and 120g of Artemisia tetragonum, add water and boil three times; add 8 times the amount of water for the first time, soak for 30 minutes and then boil for 2 hours, add 6 times the amount of water for the second and third times and boil for 1.5 hours. Filter, combine the filtrate, concentrate to a concentration of 2.5g / ml (based on the original medicinal materials), sterilize, and prepare an oral solution.
[0042] Example 3
[0043] This embodiment discloses a method for preparing the composition of the present invention, which is as follows:
[0044] Weigh 100g of Coxixian and 120g of Artemisia tetragonum, add water and boil three times; add 6 times the amount of water for the first time, soak for 30min and boil for 2h, add 5 times the amount of water for the second and third times and boil for 1h. Filter, combine the filtrate, concentrate into a thick paste with a relative density of 1.34 at 60℃, add 80g of dextrin, wet granulate, dry, and obtain granules.
[0045] Example 4
[0046] This embodiment discloses a method for preparing the composition of the present invention, which is as follows:
[0047] Take 120g of Coxixian and 80g of Artemisia tetragonum, add water and boil three times; add 6 times the amount of water for the first time, soak for 30 minutes and boil for 2 hours, add 6 times the amount of water for the second and third times and boil for 2 hours. Filter, combine the filtrate, concentrate to a concentration of 2g / ml (based on the original medicinal materials), sterilize, and prepare an oral solution.
[0048] Example 5
[0049] This embodiment discloses a method for preparing the composition of the present invention, which is as follows:
[0050] Take 120g of Coxixian and 100g of Artemisia tetragonum, add water and boil twice; add 8 times the amount of water for the first time, soak for 30 minutes and then boil for 2 hours, and add 6 times the amount of water for the second time and boil for 2 hours. Filter, combine the filtrate, concentrate to a concentration of 2g / ml (based on the original medicinal materials), sterilize, and prepare an oral solution.
[0051] Test Example 1
[0052] This test example discloses the pharmacodynamic test of the composition of the present invention.
[0053] In this test example, a high-iodine-induced Hashimoto's thyroiditis mouse model was constructed and the composition of the present invention was administered for intervention to observe the therapeutic effect of the composition of the present invention on Hashimoto's thyroiditis mice.
[0054] 1. Drug: The drug used in this test example is a 2 g / ml concentrated solution prepared according to the method of Example 1.
[0055] 2. Animals and Grouping
[0056] Thirty-five healthy female SPF NOD.H-2h4 mice aged 6-8 weeks were randomly divided into a blank control group (n=7) and a model control group (n=28) after adaptive feeding for 1 week. Each group was fed with ordinary feed. The mice in the blank control group were given ordinary sterile water, and the mice in the model control group drank 50 mg / L NaI sterile water. The intervention lasted for 10 weeks.
[0057] 3. Drug administration
[0058] The model control group NOD.H-2h4 female mice (n=28) were randomly divided into 4 groups: model control group (n=7), low-dose group of the composition of the present invention (n=7), medium-dose group of the composition of the present invention (n=7) and high-dose group of the composition of the present invention (n=7). The dosage of mice was calculated with reference to Xu Shuyun's "Experimental Animal Science". The low-dose group of the composition of the present invention was given 2.6g of concentrated solution / kg, the medium-dose group of the composition of the present invention was given 5.2g of concentrated solution / kg, and the high-dose group of the composition of the present invention was given 10.4g of concentrated solution / kg by gavage. The blank control group and the model control group were given an equal amount of normal saline by gavage, once a day, for 8 consecutive weeks.
[0059] 4. Sample collection and processing
[0060] After 8 weeks of drug intervention, peripheral blood and thyroid tissue were collected from each group of mice, and the body weight and thyroid wet weight of the mice were weighed.
[0061] 5 indicators detection
[0062] 5.1 Biochemical index detection
[0063] Enzyme-linked immunosorbent assay (ELISA) was used to detect serum T3, T4, FT3, FT4, TSH, TPO, and TgAb, and the changes in thyroid function were observed.
[0064] 5.2 HE staining of paraffin sections and quantitative morphological analysis
[0065] Paraffin sections were prepared, HE staining was performed, and quantitative morphological analysis of thyroid inflammation was performed to determine the degree of thyroid inflammation. 4+ CD 25+ naturally occurringregulatory T cells and not lymphopenia play a role in the pathogenesis ofiodide-induced autoimmune thyroiditis in NOD-H2 h4 mice[J].J Autoimmun,2007,29:195-202.), the thyroid inflammation degree was scored by HE staining of thyroid tissue sections, and the inflammatory cell infiltration score was evaluated based on the lymphocyte infiltration area.
[0066] 6. Results:
[0067] 6.1 Thyroid weight
[0068] The results of the investigation on the wet weight and relative weight of the thyroid gland of NOD.H-2h4 mice in each group are shown in Table 1: compared with the blank control group, the wet weight and relative weight of the thyroid gland of the mice in the model control group were increased (P < 0.01); compared with the model control group, the wet weight and relative weight of the thyroid gland of the mice in the high-dose group of the composition of the present invention were reduced (P < 0.05); the wet weight and relative weight of the thyroid gland of the mice in the low-, medium- and high-dose groups of the composition of the present invention were reduced with the increase of the drug dose, showing a certain dose-effect relationship, but the difference was not statistically significant (P > 0.05).
[0069] Table 1 Table of wet weight and relative weight of thyroid gland of NOD.H-2h4 mice in each group ([M(P25, P75)], n=35)
[0070] Group Thyroid wet weight (mg) Relative weight (mg / 100gweight) Blank control group 4.00(4.00,8.00) 13.79(12.30,23.35) Model control group 15.00(12.00,18.00)** 46.73(42.25,69.23)** Low dose group of the composition of the present invention 10.00(8.00,13.00) 42.40(27.40,48.51) Dosage group in the composition of the present invention 9.00(8.00,10.00) 30.20(25.81,37.17) High dose group of the composition of the present invention <![CDATA[7.00(6.00,8.00) △ ]]> <![CDATA[24.10(22.95,25.36) △ ]]>
[0071] In Table 1, compared with the blank control group, *P < 0.05, **P < 0.01; compared with the model control group, △ P<0.05, △△ P<0.0
[0072] 6.2 Antibodies
[0073] The results of serum thyroid autoantibody (TgAb) test in each group of NOD.H-2h4 mice are shown in Table 2 and Appendix. Figure 1 As shown: compared with the blank control group, the TgAb level of mice in the model control group increased (P < 0.01); compared with the model control group, the TgAb level of mice in the medium and high dose groups of the composition of the present invention decreased (P < 0.01). The TgAb levels of mice in the low, medium and high dose groups of the composition of the present invention decreased with the increase of drug dose, showing a certain dose-effect relationship, but the difference was not statistically significant (P > 0.05).
[0074] Table 2 NOD.H-2 in each group h4 Serum thyroid autoantibody levels (TgAb) in mice n=33)
[0075]
[0076]
[0077] Note: In Table 2, compared with the blank group, *P<0.05, **P<0.01; compared with the model control group, △ P<0.05, △△ P < 0.01;
[0078] 6.3 Pathological analysis
[0079] The incidence of thyroiditis in NOD.H-2h4 mice in each group is shown in Table 3. h4 The mouse thyroid inflammation score table is shown in Table 4, and the thyroid HE staining images of NOD.H-2h4 mice in each group are shown in the attached figure. Figure 2 The results showed that after administration, the degree of inflammatory infiltration of thyroid tissue, the incidence of Hashimoto's thyroiditis, and the Hashimoto's thyroiditis score of mice in the model control group were higher than those in the blank control group (P < 0.05); the degree of inflammatory infiltration of thyroid tissue, the incidence of Hashimoto's thyroiditis, and the Hashimoto's thyroiditis score of mice in the high-dose group of the composition of the present invention were lower than those in the model control group (P < 0.05).
[0080] Table 3 NOD.H-2 in each group h4Incidence of Hashimoto's thyroiditis in mice (n=33)
[0081]
[0082] Note: Compared with the blank group, *P<0.05, **P<0.01; Compared with the model control group, △ P<0.05, △△ P<0.01.
[0083] Table 4 NOD.H-2 in each group h4 Mouse thyroid inflammation score table (n=33)
[0084] Group 0 1 2 3 4 Average score Blank Group 6 1 0 0 0 0.14 Model control group 0 1 4 0 2 2.43* Low dose group of the composition of the present invention 2 0 4 1 0 1.57 Dosage group in the composition of the present invention 3 0 2 1 0 1.17 High dose group of the composition of the present invention 5 0 1 0 0 <![CDATA[0.33 △ ]]>
[0085] Note: Compared with the blank group, *P<0.05, **P<0.01; Compared with the model control group, △ P<0.05, △△ P<0.01.
[0086] 7. Conclusion
[0087] The thyroid tissue of the mice in the model control group was enlarged compared with that in the blank control group, and the absolute and relative weights increased. The thyroid glands of the mice in the model control group were significantly damaged, and obvious inflammatory cell infiltration could be observed under a light microscope. The incidence of Hashimoto's thyroiditis, Hashimoto's thyroiditis scores, and TgAb levels of the mice in the model control group were higher than those in the blank control group. The composition of the present invention can reduce enlarged thyroid tissue, reduce the absolute and relative weight of the thyroid glands of the mice in the model control group, reduce the inflammatory damage of the thyroid tissues of the mice in the model control group, and reduce the TgAb levels of the mice in the model control group.
[0088] In summary, the composition of the present invention can significantly improve the thyroid inflammation level of NOD.H-2h4 mice and can be used for the treatment of Hashimoto's thyroiditis.
[0089] Finally, it should be noted that the above embodiments are only preferred embodiments of the present invention to illustrate the technical solution of the present invention, but not to limit it, and certainly not to limit the patent scope of the present invention. Any changes or modifications that are made to the main design concept and spirit of the present invention without any substantial meaning, and the technical problems they solve are still consistent with the present invention, should be included in the protection scope of the present invention; in addition, the direct or indirect application of the technical solution of the present invention in other related technical fields is also included in the patent protection scope of the present invention.
Claims
1. A composition for treating Hashimoto's thyroiditis, characterized in that: The drug is prepared from the following raw materials in parts by weight: 80-120 parts of Coxid and 80-120 parts of Artemisia tetragonum.
2. A composition for treating Hashimoto's thyroiditis according to claim 1, characterized in that: The drug is prepared from the following raw materials in parts by weight: 90 to 110 parts of Coxid and 90 to 110 parts of Artemisia tetragonum.
3. A composition for treating Hashimoto's thyroiditis according to claim 1, characterized in that: The method is prepared from the following raw materials in parts by weight: 100 parts of Coxixin and 100 parts of Artemisia tetragonum.
4. A composition for treating Hashimoto's thyroiditis according to any one of claims 1 to 3, characterized in that: The composition is an oral preparation prepared by using coxixin and Artemisia tetragonum as raw materials.
5. A composition for treating Hashimoto's thyroiditis according to claim 4, characterized in that: The oral preparations include oral solid preparations, oral liquid preparations, and oral semisolid preparations.
6. A method for preparing a composition for treating Hashimoto's thyroiditis according to any one of claims 1 to 5, characterized in that: The steps include: Weigh cosihan and Artemisia tetragonum according to proportion, add water to extract, concentrate and prepare an oral solution.
7. A method for preparing a composition for treating Hashimoto's thyroiditis according to any one of claims 1 to 5, characterized in that: The steps include: Weigh Coxixin and Artemisia tetragonum according to proportion, add water to extract, concentrate into a thick paste, add auxiliary materials, granulate, dry, and prepare granules.
8. The preparation method according to claim 6 or 7, characterized in that: The number of times of adding water and boiling is 1 to 5 times, preferably 1 to 3 times; Add 5 to 8 times more water each time; Preferably, before the first decoction, soak in water for 0.5 to 2 hours.
9. Use of the composition according to any one of claims 1 to 5 in the preparation of a medicament for preventing and / or treating thyroiditis.
10. The use according to claim 9, characterized in that: Application in the preparation of drugs for preventing or / treating Hashimoto's thyroiditis.
